Abstract
The metabolic syndrome represents a constellation of co-morbidities that include central adiposity, insulin resistance, dyslipidemia and hypertension, which results from an elevated prevalence of obesity. An increased abdominal adiposity is observed in upperbody obesity with preferential accumulation of fat in the visceral depot, which renders these individuals more prone to metabolic and cardiovascular problems. The pathophysiology of the metabolic syndrome seems to be closely associated to an elevated efflux of free fatty acids from the visceral fat compartment and a dysregulation of the expression of adipose tissue-derived factors (also termed “adipokines”). Weight reduction and increased physical activity represent the main approach to tackle the “diabesity” epidemic. Nonetheless, taking advantage of the different biochemical and molecular characteristics of visceral and subcutaneous adipose tissue may open up novel pharmacological strategies to combat the metabolic and cardiovascular derangements accompanying the metabolic syndrome.
Keywords: Cathecolamines, stimulatory GTP-binding protein, free fatty acids, Natriuretic peptides, lipolysis, Adiponectin
Current Pharmaceutical Design
Title: Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?
Volume: 13 Issue: 21
Author(s): Amaia Rodriguez, Victoria Catalan, Javier Gomez-Ambrosi and Gema Fruhbeck
Affiliation:
Keywords: Cathecolamines, stimulatory GTP-binding protein, free fatty acids, Natriuretic peptides, lipolysis, Adiponectin
Abstract: The metabolic syndrome represents a constellation of co-morbidities that include central adiposity, insulin resistance, dyslipidemia and hypertension, which results from an elevated prevalence of obesity. An increased abdominal adiposity is observed in upperbody obesity with preferential accumulation of fat in the visceral depot, which renders these individuals more prone to metabolic and cardiovascular problems. The pathophysiology of the metabolic syndrome seems to be closely associated to an elevated efflux of free fatty acids from the visceral fat compartment and a dysregulation of the expression of adipose tissue-derived factors (also termed “adipokines”). Weight reduction and increased physical activity represent the main approach to tackle the “diabesity” epidemic. Nonetheless, taking advantage of the different biochemical and molecular characteristics of visceral and subcutaneous adipose tissue may open up novel pharmacological strategies to combat the metabolic and cardiovascular derangements accompanying the metabolic syndrome.
Export Options
About this article
Cite this article as:
Amaia Rodriguez , Victoria Catalan , Javier Gomez-Ambrosi and Gema Fruhbeck , Visceral and Subcutaneous Adiposity: Are Both Potential Therapeutic Targets for Tackling the Metabolic Syndrome?, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039599
DOI https://dx.doi.org/10.2174/138161207781039599 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Diabetic Heart and the Cardiovascular Surgeon
Cardiovascular & Hematological Disorders-Drug Targets Autoimmune Polyendocrine Syndrome Complicated by Pulmonary Hypertension
Endocrine, Metabolic & Immune Disorders - Drug Targets Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued) Oral Disintegrating Tablets – An Updated Patent Perspective
Recent Patents on Drug Delivery & Formulation Enzyme Inhibition by Peroxynitrite-Mediated Tyrosine Nitration and Thiol Oxidation
Current Enzyme Inhibition New Insights into Adipokines as Potential Biomarkers for Type-2 Diabetes Mellitus
Current Medicinal Chemistry Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
Mini-Reviews in Medicinal Chemistry Protective Role of Diabetes Mellitus on Abdominal Aortic Aneurysm Pathogenesis: Myth or Reality?
Current Vascular Pharmacology Is Atorvastatin Superior to Other Statins? Analysis of the Clinical Trials with Atorvastatin Having Cardiovascular Endpoints
Reviews on Recent Clinical Trials Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Aging Related Changes in Mixed Basal Saliva Concentration of Sodium, Potassium and Chloride in Healthy Non Medicated Humans
Current Aging Science Effect of Ouabain on the Immune System
Current Hypertension Reviews Anti-Angiogenic Therapy in Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Inflammaging in Skin and other Tissues - The Roles of Complement System and Macrophage
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacotherapy of Sickle Cell Disease in Children
Current Pharmaceutical Design Pharmacogenomics: Integration into Drug Discovery and Development
Current Topics in Medicinal Chemistry Unfolding Cardiac Amyloidosis –From Pathophysiology to Cure
Current Medicinal Chemistry Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Angiogenesis Inhibitors and Vascular Disrupting Agents in Non-Small Cell Lung Cancer
Current Medicinal Chemistry Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design